KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2016 - 2025)

Regeneron Pharmaceuticals has reported Cash from Financing Activities over the past 17 years, most recently at -$780.1 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$780.1 million for Q4 2025, up 31.3% from a year ago — trailing twelve months through Dec 2025 was -$3.7 billion (down 68.84% YoY), and the annual figure for FY2025 was -$3.7 billion, down 68.84%.
  • Cash from Financing Activities for Q4 2025 was -$780.1 million at Regeneron Pharmaceuticals, down from -$717.9 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for REGN hit a ceiling of $385.4 million in Q3 2021 and a floor of -$1.1 billion in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was -$462.1 million (2023), compared with a mean of -$486.0 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 117.66% in 2022 and later tumbled 2412.53% in 2025.
  • Regeneron Pharmaceuticals' Cash from Financing Activities stood at -$906.6 million in 2021, then skyrocketed by 72.69% to -$247.6 million in 2022, then crashed by 80.17% to -$446.1 million in 2023, then tumbled by 154.54% to -$1.1 billion in 2024, then skyrocketed by 31.3% to -$780.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$780.1 million (Q4 2025), -$717.9 million (Q3 2025), and -$1.1 billion (Q2 2025) per Business Quant data.